JP2012521346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012521346A5 JP2012521346A5 JP2011547867A JP2011547867A JP2012521346A5 JP 2012521346 A5 JP2012521346 A5 JP 2012521346A5 JP 2011547867 A JP2011547867 A JP 2011547867A JP 2011547867 A JP2011547867 A JP 2011547867A JP 2012521346 A5 JP2012521346 A5 JP 2012521346A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- ctprosp
- human
- isolated protein
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims 20
- 108090000623 proteins and genes Proteins 0.000 claims 20
- 241000283690 Bos taurus Species 0.000 claims 7
- 241000282560 Macaca mulatta Species 0.000 claims 7
- 241000772415 Neovison vison Species 0.000 claims 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 claims 1
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 12
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 description 12
- 102200138902 rs9606756 Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000012528 membrane Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14854109P | 2009-01-30 | 2009-01-30 | |
| EP09151790 | 2009-01-30 | ||
| US61/148,541 | 2009-01-30 | ||
| EP09151790.4 | 2009-01-30 | ||
| PCT/SE2010/050097 WO2010087771A1 (en) | 2009-01-30 | 2010-01-29 | Compound and method for treatment of alzheimer's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012521346A JP2012521346A (ja) | 2012-09-13 |
| JP2012521346A5 true JP2012521346A5 (https=) | 2014-03-27 |
| JP5801206B2 JP5801206B2 (ja) | 2015-10-28 |
Family
ID=40707673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011547867A Active JP5801206B2 (ja) | 2009-01-30 | 2010-01-29 | アルツハイマー病の治療のための化合物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8785390B2 (https=) |
| EP (1) | EP2391379B1 (https=) |
| JP (1) | JP5801206B2 (https=) |
| CN (1) | CN102300582A (https=) |
| WO (1) | WO2010087771A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102300582A (zh) * | 2009-01-30 | 2011-12-28 | 阿尔法贝塔公司 | 用于治疗阿尔茨海默病的化合物和方法 |
| WO2011162655A1 (en) | 2010-06-24 | 2011-12-29 | Alphabeta Ab | Compound and method for treatment of alzheimer's disease and familial dementia |
| WO2012138284A1 (en) * | 2011-04-05 | 2012-10-11 | Alphabeta Ab | Amyloidosis target useful in methods of treatment and for screening of compounds |
| ES2571055B1 (es) * | 2016-02-15 | 2016-12-28 | Araclon Biotech, S.L. | Conjugado amiloide y usos y procedimientos del mismo |
| CN114107254A (zh) * | 2021-11-12 | 2022-03-01 | 武汉理工大学 | 一种重组蛋白DspB-SNa5及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0290516A4 (en) | 1986-10-24 | 1989-11-14 | Jeffrey A Whitsett | PROTEINS RELATED TO SURFACE-EFFECTIVE HYDROPHOBIC LUNG ACTIVE SUBSTANCES. |
| US6670195B1 (en) | 1999-05-26 | 2003-12-30 | New York University | Mutant genes in Familial British Dementia and Familial Danish Dementia |
| US20030224982A1 (en) * | 2001-07-05 | 2003-12-04 | Li Li | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US6673545B2 (en) | 2000-07-28 | 2004-01-06 | Incyte Corporation | Prostate cancer markers |
| US6716589B2 (en) | 2000-11-20 | 2004-04-06 | Alphabeta Ab | Discordant helix stabilization for prevention of amyloid formation |
| WO2003090682A2 (en) * | 2002-04-25 | 2003-11-06 | The Scripps Research Institute | Treatment and prevention of pulmonary conditions |
| WO2004056310A2 (en) | 2002-12-09 | 2004-07-08 | Children's Hospital Medical Center | Methods of diagnosis and treatment of interstitial lung disease |
| GB0307863D0 (en) * | 2003-04-04 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic treatment |
| CA2537844A1 (en) | 2003-09-05 | 2005-03-17 | Cellzome Ag | Treatment of neurodegenerative diseases |
| JP4796967B2 (ja) | 2003-11-07 | 2011-10-19 | ヴァーミリオン インコーポレイテッド | アルツハイマー病のためのバイオマーカー |
| AU2004296206A1 (en) * | 2003-12-04 | 2005-06-23 | The Scripps Research Institute | Treatment and preventions of asthma |
| CA2579710C (en) | 2004-04-05 | 2013-01-08 | The University Of Tokushima | Antigen-drug vehicle enabling transmucosal and transdermal administration, and method of inducing mucosal immunity and mucosal vaccine and dds using the same |
| AU2006259482A1 (en) | 2005-06-14 | 2006-12-28 | Albert Einstein College Of Medicine Of Yeshiva University | Effect of BRI proteins on abeta production |
| WO2007005672A2 (en) * | 2005-06-30 | 2007-01-11 | The Scripps Research Institute | Treatment and prevention of respiratory diseases and conditions |
| EP1930025B1 (en) | 2005-08-05 | 2013-05-01 | The University of Tokushima | ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE |
| CA2706535A1 (en) | 2006-11-22 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Transgenic mammals modified in bri protein expression |
| US20100284969A1 (en) | 2007-06-05 | 2010-11-11 | Frank Guarnieri | Methods and Compositions for Delivery of Medicaments to the Lungs |
| US20100298202A1 (en) * | 2007-07-06 | 2010-11-25 | Mayo Foundation For Medical Education And Research | Bri polypeptides and reducing ab aggregation |
| CN102300582A (zh) | 2009-01-30 | 2011-12-28 | 阿尔法贝塔公司 | 用于治疗阿尔茨海默病的化合物和方法 |
| WO2011162655A1 (en) | 2010-06-24 | 2011-12-29 | Alphabeta Ab | Compound and method for treatment of alzheimer's disease and familial dementia |
| WO2012138284A1 (en) | 2011-04-05 | 2012-10-11 | Alphabeta Ab | Amyloidosis target useful in methods of treatment and for screening of compounds |
-
2010
- 2010-01-29 CN CN201080005669XA patent/CN102300582A/zh active Pending
- 2010-01-29 EP EP10736110.7A patent/EP2391379B1/en not_active Not-in-force
- 2010-01-29 WO PCT/SE2010/050097 patent/WO2010087771A1/en not_active Ceased
- 2010-01-29 JP JP2011547867A patent/JP5801206B2/ja active Active
- 2010-01-29 US US13/145,096 patent/US8785390B2/en active Active
-
2014
- 2014-05-16 US US14/279,589 patent/US9402883B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20210027377A (ko) | 프로그래뉼린을 포함하는 융합 단백질 | |
| Uppalapati et al. | A potent D-protein antagonist of VEGF-A is nonimmunogenic, metabolically stable, and longer-circulating in vivo | |
| JP2018119011A (ja) | アルツハイマー病治療方法 | |
| US9051364B2 (en) | Composition for producing anti-amyloid beta peptide antibodies with D-peptides | |
| AR062065A1 (es) | Anticuerpo humanizado | |
| JP2012521346A5 (https=) | ||
| NZ591130A (en) | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof | |
| Forde et al. | Potential of host defense peptide prodrugs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis | |
| KR20220130678A (ko) | 프로그라눌린 변이체들 | |
| CN102105485B (zh) | 选择性胱天蛋白酶抑制剂及其用途 | |
| JP2012115277A5 (https=) | ||
| CN111057134B (zh) | 一类具有广谱抗菌活性、低毒性且无诱导耐药性的抗菌肽及其应用 | |
| JP2015504052A5 (https=) | ||
| JP2014506450A5 (https=) | ||
| CN110563802B (zh) | 一组含n-甲基化氨基酸及n端脂肪酸修饰的抗菌肽类似物及其合成方法和应用 | |
| WO2021247675A1 (en) | Coronavirus-binding agents and uses thereof | |
| FI4034555T3 (fi) | Dap10/dap12-fuusiopolypeptidit | |
| EP4077348A1 (en) | Retro-inverso peptides | |
| RU2010120571A (ru) | Тимус-специфический белок | |
| JP2019038772A5 (https=) | ||
| CN101466729A (zh) | 溶杆菌素酰胺 | |
| JP2015525237A5 (https=) | ||
| JP2015533372A5 (https=) | ||
| RU2015114320A (ru) | Пептидные антагонисты рецептора 2 вазопрессина | |
| WO2011144714A1 (en) | Kissorphin peptides for use in the treatment of alzheimer's disease, creutzfeldt- jakob disease or diabetes mellitus |